GlassScriptPhysician profile
Nabil Khoury
NPI 1053366351
$2,043.66
in general payments reported to CMS, 2019-2025
11 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $97.99 · 2021: $27.69 · 2022: $516 · 2023: $132 · 2024: $348 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $781.02 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Shionogi INC | $481.88 | 2020-2025 | Fetroja |
| Melinta Therapeutics, LLC | $321.08 | 2019-2024 | Kimyrsa, Rezzayo, Vabomere |
| Amarin Pharma, INC. | $118.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.73 | 2024 | |
| Gilead Sciences, INC. | $107.96 | 2019 | |
| Paratek Pharmaceuticals, INC. | $36.45 | 2024 | Nuzyra |
| Abbvie INC. | $21.73 | 2022 | |
| Braintree Laboratories, INC. | $21.33 | 2020 | |
| Smith+Nephew, INC. | $18.49 | 2025 | Renasys Touch |
| Ferring Pharmaceuticals INC. | $17.73 | 2024 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Khoury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.